Clinical Trial Detail

NCT ID NCT02599649
Title Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

bone marrow cancer

Therapies

Nivolumab

Azacitidine

Lirilumab

Age Groups: adult

No variant requirements are available.